Ep. 172 - AACR Insights
BioCentury This Week
00:00
Introduction
This week, we're zeroing in on the 2023 AACR annual meeting. One thing that stood out to me this year was the limited number of new immuno oncology targets. In past years, we've seen a lot of excitement around checkpoints and innate immune modulatory functions. And there wasn't much of that this year.
Transcript
Play full episode
